Vicuron Pharmaceuticals was acquired by Pfizer in September 2005, then was subsequently sold in December 2009 to Durata Therapeutics Inc. Since then, the firm has operated as a subsiduary of Darata. Vicuron Pharmaceuticals, Inc. offers discovery, development, manufacture, and marketing of antibiotic drugs. The companyâs products include Dalbavancin, a long-acting, injectable, lipoglycopeptide antibiotic in late-stage clinical development. Dalbavancin offers activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The companyâs products also include ramoplanin, which is an oral nonabsorbable form of antibiotic that selectively inhibits Gram-positive bacteria, and various types of vancomycin-resistant enterococci and Clostridia. In addition, it provides VIC-Acne, a topical antibiotic cream that is in Phase I clinical trial. Vicuron Pharmaceuticals, Inc. has research collaboration agreements with Novartis Pharma AG to develop deformylase inhibitors as new antibacterial agents and to provide target-based screens; and Pfizer, Inc. to discover second and third generation oxazolidinone
